Commercial Inventions
Monoclonal Antibodies against Bacteriophage M13
The technology for Monoclonal Antibodies (MAbs) against two coat proteins
gIIIp and gVIIIp of filamentous phage M13 and a process for their preparation
was licensed to Pharmacia Biotech. Inc., USA, presently GE Healthcare Life
Sciences who manufacture and market under product code 27-9420-01 and
27-9421-01. This project was supported by DBT and the transfer of
technology happened in 1998. This fetched $20,000 as the one-time licensing
fee and was perhaps the first technology transfer through DBT-supported
project and one of the earliest Indian patents granted for a Biotech Product!
“NEVA HIV” – A test for on-site detection of HIV
This test detects antibodies to HIV-1 and HIV-2 in two minutes using a drop of blood. The test requires no instrument, electricity, not even water from outside, and can be performed by a semi- skilled technician in any primary health center.
This novel technology was introduced to the Nation by Hon’ble Vice
President of India, on the occasion of the National Technology Day, the 11th
May, 2001. NEVA HIV is a totally indigenous technology and was transferred
to Cadila Pharmaceuticals Limited, Ahmedabad.
“TB Confirm” – A Rapid Visual Test for detection of Tuberculosis causing
bacteria in culture
This Immuno-chromatographic test allows for easy and rapid screening of specimen for confirmation of growth of tuberculosis causing bacterium Mycobacterium tuberculosis (Mtb). This test can be performed with minimal training and provides results in less than twenty minutes. The test is based on detection of two Mtb- specific antigens using high affinity monoclonal antibodies. It has been evaluated on clinical specimens grown in liquid medium and LJ slant with near 100% sensitivity and 100% specificity. This Immuno-chromatographic test allows for easy and rapid screening of specimen for confirmation of growth of tuberculosis causing bacterium Mycobacterium tuberculosis (Mtb). Licensed to M/s Span Diagnostics Ltd, Surat. Evaluated at laboratories of Dr Sarman Singh (AIIMS, New Delhi) and Dr. Camila Rodrigues (P.D.Hinduja Hospital, Mumbai).